CSF Biomarker Panel May Improve Diagnosis of CNS Lymphoma
TOPLINEA cerebrospinal fluid (CSF) biomarker panel, combining MYD88 mutation testing with interleukin 10 (IL-10) and C-X-C motif chemokine ligand 13 (CXCL13) measurements, showed high specificity for CNS lymphoma and correctly identified more than half of the CNS lymphoma cases. With further validation, this panel could help reduce reliance on invasive brain biopsy in selected patients, the authors suggested.METHODOLOGYBrain biopsy remains the reference standard for diagnosing primary CNS lymphoma but can be risky and contribute to diagnostic delays. CSF biomarkers, such as the MYD88 mutation, IL-10, and CXCL13, have shown promise in identifying CNS lymphoma, but most evidence has come from retrospective studies.
- ▪TOPLINEA cerebrospinal fluid (CSF) biomarker panel, combining MYD88 mutation testing with interleukin 10 (IL-10) and C-X-C motif chemokine ligand 13 (CXCL13) measurements, showed high specificity for CNS lymphoma and correctly identified mo
- ▪With further validation, this panel could help reduce reliance on invasive brain biopsy in selected patients, the authors suggested.METHODOLOGYBrain biopsy remains the reference standard for diagnosing primary CNS lymphoma but can be risky
- ▪CSF biomarkers, such as the MYD88 mutation, IL-10, and CXCL13, have shown promise in identifying CNS lymphoma, but most evidence has come from retrospective studies.
Opening excerpt (first ~120 words) tap to expand
TOPLINEA cerebrospinal fluid (CSF) biomarker panel, combining MYD88 mutation testing with interleukin 10 (IL-10) and C-X-C motif chemokine ligand 13 (CXCL13) measurements, showed high specificity for CNS lymphoma and correctly identified more than half of the CNS lymphoma cases. With further validation, this panel could help reduce reliance on invasive brain biopsy in selected patients, the authors suggested.METHODOLOGYBrain biopsy remains the reference standard for diagnosing primary CNS lymphoma but can be risky and contribute to diagnostic delays. CSF biomarkers, such as the MYD88 mutation, IL-10, and CXCL13, have shown promise in identifying CNS lymphoma, but most evidence has come from retrospective studies.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
